INS and type 2 diabetes mellitus: Dosing and titration strategies for icodec were tested to help inform phase 3 studiesthrough a series of phase 2 studies, all in patients with T2D: 2 in insulin-naivepatients (111, 112) and 1 in those already on once-daily basal insulin (113).